| Symbol | NAGE |
|---|---|
| Name | NIAGEN BIOSCIENCE, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medicinal Chemicals and Botanical Products |
| Address | 10900 WILSHIRE BLVD.,SUITE 600, LOS ANGELES, California, 90024, United States |
| Telephone | +1 -310 388-6706 |
| Fax | — |
| — | |
| Website | https://www.niagenbioscience.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001386570 |
| Description | Niagen is one of the most advanced, scientifically researched NAD precursors, proven to restore what aging takes away. Backed by 35 clinical studies, protected by global patents, and trusted by leading researchers, it is the foundation of cellular vitality and optimal healthspan. Additional info from NASDAQ: |
Director YU Wing Tak Wendy 🟢 acquired 31.7K shares (1 derivative) of Niagen Bioscience, Inc. (NAGE) at $3.45 Transaction Date: Jun 24, 2026 | Filing ID: 000001
Read moreDirector Ng Wang Yu Gary 🟢 acquired 31.7K shares (1 derivative) of Niagen Bioscience, Inc. (NAGE) at $3.45 Transaction Date: Jun 24, 2026 | Filing ID: 000001
Read moreDirector Cohen Ann 🟢 acquired 31.7K shares (1 derivative) of Niagen Bioscience, Inc. (NAGE) at $3.45 Transaction Date: Jun 24, 2026 | Filing ID: 000001
Read moreDirector Patrick Kristin 🟢 acquired 31.7K shares (1 derivative) of Niagen Bioscience, Inc. (NAGE) at $3.45 Transaction Date: Jun 24, 2026 | Filing ID: 000003
Read moreDirector Shahbazi Hamed 🟢 acquired 31.7K shares (1 derivative) of Niagen Bioscience, Inc. (NAGE) at $3.45 Transaction Date: Jun 24, 2026 | Filing ID: 000001
Read moreDirector Rubin Steven D 🟢 acquired 31.7K shares (1 derivative) of Niagen Bioscience, Inc. (NAGE) at $3.45 Transaction Date: Jun 24, 2026 | Filing ID: 000001
Read moreDirector Jaksch Frank L Jr 🟢 acquired 31.7K shares (1 derivative) of Niagen Bioscience, Inc. (NAGE) at $3.45 Transaction Date: Jun 24, 2026 | Filing ID: 000001
Read moreNiagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
Read moreNiagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
Read more